Azactam


Also found in: Thesaurus, Medical.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.Azactam - an antibiotic (trade name Azactam) used against severe infections; has minimal side effects
antibiotic, antibiotic drug - a chemical substance derivable from a mold or bacterium that can kill microorganisms and cure bacterial infections; "when antibiotics were first discovered they were called wonder drugs"
trademark - a formally registered symbol identifying the manufacturer or distributor of a product
References in periodicals archive ?
5 billion in 2011, which helped offset the loss of revenues from a number of EDT legacy products including Azactam, Maxipime and Prialt, which contributed $41.
The eleven antimicrobial agents used in this study were: Ampicillin (AMP), Augmentin (AUG), Azactam (AZT), Ceftriaxone (CR0), Cefotaxime (CIX), Ceftazidime (CAZ), Ciprofloxacin (CIP), Gentamicin (GEN), Imipenem (IMP), Tetracycline (TEl) and Tobramicin (lOB).
It is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb.
We have about 600 employees working at the BMS complex in Humacao manufacturing other key company products such as Avapro, Monopril, Pravachol, Corgard, Zerit, Azactam, Serzone, and its best-selling diabetes treatment drug, Glucophage.
Elan ceased distributing Azactam and Maxipime in 2010.
2 million in the quarter, offsetting revenue loss from legacy products including Azactam, Prialt, Maxipime and Skelaxin, which contributed $38.
The company has announced that it plans to find buyers for Azactam, Maxipime and Abelcet, three drugs used by hospitals to fight infections.
Elan ceased distributing Azactam as of March 31, 2010, and Maxipime as of September 30, 2010.
Comments: Revenue from the BioNeurology business was up 7% for the year boosted by Tysabri sales, while revenue from Elan Drug Technologies (EDT) fell due to reduced revenue from Maxipime, Azactam and Prialt.
Comments: Biopharmaceutical business revenue was up 28% driven by Tysabri sales, offsetting reduced sales of Azactam and Maxipime.
The increase was primarily due to the 20% growth in global in-market net sales of Tysabri, which more than offset the cessation of revenues from Azactam, Prialt and Maxipime.
The increased gross margin principally reflects higher sales of Tysabri and the Ampyra launch, which more than offset lower revenues from Maxipime, Azactam, Skelaxin and Prialt.